Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma
Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the se...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
1987 |
|---|
| Umfang: |
6 |
|---|
| Reproduktion: |
Springer Online Journal Archives 1860-2002 |
|---|---|
| Übergeordnetes Werk: |
in: Rheumatology international - 1981, 7(1987) vom: März, Seite 127-132 |
| Übergeordnetes Werk: |
volume:7 ; year:1987 ; month:03 ; pages:127-132 ; extent:6 |
| Links: |
|---|
| Katalog-ID: |
NLEJ203145682 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ203145682 | ||
| 003 | DE-627 | ||
| 005 | 20210706120809.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 070528s1987 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)NLEJ203145682 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| 264 | 1 | |c 1987 | |
| 300 | |a 6 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. | ||
| 533 | |f Springer Online Journal Archives 1860-2002 | ||
| 700 | 1 | |a Lemmel, E. M. |4 oth | |
| 700 | 1 | |a Franke, M. |4 oth | |
| 700 | 1 | |a Gaus, W. |4 oth | |
| 700 | 1 | |a Hartl, P. W. |4 oth | |
| 700 | 1 | |a Hofschneider, P. H. |4 oth | |
| 700 | 1 | |a Miehlke, K. |4 oth | |
| 700 | 1 | |a Machalke, K. |4 oth | |
| 700 | 1 | |a Obert, H. J. |4 oth | |
| 773 | 0 | 8 | |i in |t Rheumatology international |d 1981 |g 7(1987) vom: März, Seite 127-132 |w (DE-627)NLEJ188987827 |w (DE-600)1464208-6 |x 1437-160X |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:1987 |g month:03 |g pages:127-132 |g extent:6 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/BF00270465 |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-SOJ | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 1987 |c 3 |h 127-132 |g 6 | ||
| matchkey_str |
article:1437160X:1987----::eutoahsiciiatilnramnoremtiatrtsihe |
|---|---|
| hierarchy_sort_str |
1987 |
| publishDate |
1987 |
| allfields |
(DE-627)NLEJ203145682 DE-627 ger DE-627 rakwb eng Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma 1987 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. Springer Online Journal Archives 1860-2002 Lemmel, E. M. oth Franke, M. oth Gaus, W. oth Hartl, P. W. oth Hofschneider, P. H. oth Miehlke, K. oth Machalke, K. oth Obert, H. J. oth in Rheumatology international 1981 7(1987) vom: März, Seite 127-132 (DE-627)NLEJ188987827 (DE-600)1464208-6 1437-160X nnns volume:7 year:1987 month:03 pages:127-132 extent:6 http://dx.doi.org/10.1007/BF00270465 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 7 1987 3 127-132 6 |
| spelling |
(DE-627)NLEJ203145682 DE-627 ger DE-627 rakwb eng Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma 1987 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. Springer Online Journal Archives 1860-2002 Lemmel, E. M. oth Franke, M. oth Gaus, W. oth Hartl, P. W. oth Hofschneider, P. H. oth Miehlke, K. oth Machalke, K. oth Obert, H. J. oth in Rheumatology international 1981 7(1987) vom: März, Seite 127-132 (DE-627)NLEJ188987827 (DE-600)1464208-6 1437-160X nnns volume:7 year:1987 month:03 pages:127-132 extent:6 http://dx.doi.org/10.1007/BF00270465 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 7 1987 3 127-132 6 |
| allfields_unstemmed |
(DE-627)NLEJ203145682 DE-627 ger DE-627 rakwb eng Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma 1987 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. Springer Online Journal Archives 1860-2002 Lemmel, E. M. oth Franke, M. oth Gaus, W. oth Hartl, P. W. oth Hofschneider, P. H. oth Miehlke, K. oth Machalke, K. oth Obert, H. J. oth in Rheumatology international 1981 7(1987) vom: März, Seite 127-132 (DE-627)NLEJ188987827 (DE-600)1464208-6 1437-160X nnns volume:7 year:1987 month:03 pages:127-132 extent:6 http://dx.doi.org/10.1007/BF00270465 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 7 1987 3 127-132 6 |
| allfieldsGer |
(DE-627)NLEJ203145682 DE-627 ger DE-627 rakwb eng Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma 1987 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. Springer Online Journal Archives 1860-2002 Lemmel, E. M. oth Franke, M. oth Gaus, W. oth Hartl, P. W. oth Hofschneider, P. H. oth Miehlke, K. oth Machalke, K. oth Obert, H. J. oth in Rheumatology international 1981 7(1987) vom: März, Seite 127-132 (DE-627)NLEJ188987827 (DE-600)1464208-6 1437-160X nnns volume:7 year:1987 month:03 pages:127-132 extent:6 http://dx.doi.org/10.1007/BF00270465 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 7 1987 3 127-132 6 |
| allfieldsSound |
(DE-627)NLEJ203145682 DE-627 ger DE-627 rakwb eng Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma 1987 6 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. Springer Online Journal Archives 1860-2002 Lemmel, E. M. oth Franke, M. oth Gaus, W. oth Hartl, P. W. oth Hofschneider, P. H. oth Miehlke, K. oth Machalke, K. oth Obert, H. J. oth in Rheumatology international 1981 7(1987) vom: März, Seite 127-132 (DE-627)NLEJ188987827 (DE-600)1464208-6 1437-160X nnns volume:7 year:1987 month:03 pages:127-132 extent:6 http://dx.doi.org/10.1007/BF00270465 GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE AR 7 1987 3 127-132 6 |
| language |
English |
| source |
in Rheumatology international 7(1987) vom: März, Seite 127-132 volume:7 year:1987 month:03 pages:127-132 extent:6 |
| sourceStr |
in Rheumatology international 7(1987) vom: März, Seite 127-132 volume:7 year:1987 month:03 pages:127-132 extent:6 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
Rheumatology international |
| authorswithroles_txt_mv |
Lemmel, E. M. @@oth@@ Franke, M. @@oth@@ Gaus, W. @@oth@@ Hartl, P. W. @@oth@@ Hofschneider, P. H. @@oth@@ Miehlke, K. @@oth@@ Machalke, K. @@oth@@ Obert, H. J. @@oth@@ |
| publishDateDaySort_date |
1987-03-01T00:00:00Z |
| hierarchy_top_id |
NLEJ188987827 |
| id |
NLEJ203145682 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ203145682</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706120809.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1987 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ203145682</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1987</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lemmel, E. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franke, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gaus, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hartl, P. W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofschneider, P. H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miehlke, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Machalke, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Obert, H. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Rheumatology international</subfield><subfield code="d">1981</subfield><subfield code="g">7(1987) vom: März, Seite 127-132</subfield><subfield code="w">(DE-627)NLEJ188987827</subfield><subfield code="w">(DE-600)1464208-6</subfield><subfield code="x">1437-160X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:1987</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:127-132</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00270465</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">1987</subfield><subfield code="c">3</subfield><subfield code="h">127-132</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| series2 |
Springer Online Journal Archives 1860-2002 |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ188987827 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| collection |
NL |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1437-160X |
| topic_title |
Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
e m l em eml m f mf w g wg p w h pw pwh p h h ph phh k m km k m km h j o hj hjo |
| hierarchy_parent_title |
Rheumatology international |
| hierarchy_parent_id |
NLEJ188987827 |
| hierarchy_top_title |
Rheumatology international |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ188987827 (DE-600)1464208-6 |
| title |
Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| spellingShingle |
Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| ctrlnum |
(DE-627)NLEJ203145682 |
| title_full |
Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| journal |
Rheumatology international |
| journalStr |
Rheumatology international |
| lang_code |
eng |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1987 |
| contenttype_str_mv |
zzz |
| container_start_page |
127 |
| container_volume |
7 |
| physical |
6 |
| format_se |
Elektronische Aufsätze |
| title_sort |
results of a phase-ii clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| title_auth |
Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| abstract |
Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. |
| abstractGer |
Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. |
| abstract_unstemmed |
Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed. |
| collection_details |
GBV_USEFLAG_U ZDB-1-SOJ GBV_NL_ARTICLE |
| title_short |
Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma |
| url |
http://dx.doi.org/10.1007/BF00270465 |
| remote_bool |
true |
| author2 |
Lemmel, E. M. Franke, M. Gaus, W. Hartl, P. W. Hofschneider, P. H. Miehlke, K. Machalke, K. Obert, H. J. |
| author2Str |
Lemmel, E. M. Franke, M. Gaus, W. Hartl, P. W. Hofschneider, P. H. Miehlke, K. Machalke, K. Obert, H. J. |
| ppnlink |
NLEJ188987827 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth |
| up_date |
2024-07-06T09:55:11.721Z |
| _version_ |
1803823047478607872 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ203145682</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210706120809.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">070528s1987 xx |||||o 00| ||eng c</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ203145682</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Results of a phase-II clinical trial on treatment of rheumatoid arthritis with recombinant interferon-gamma</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">1987</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">6</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Summary In an open, non-randomized clinical trial conducted at multiple centres, 49 patients with rheumatoid arthritis were treated with recombinant interferon-gamma for 20 days. The study was carried out in two sub-studies. In the first, the total daily dose of interferon-gamma was 50 μg; in the second, 100 μg. Of the 49 cases, 40 were evaluable for statistical analysis; 24 of these patients (60%) responded to therapy, according to the criteria of a successful outcome laid down in the study protocol, and were classified as responders. In responders, the clinical parameters investigated improved with both dosages. The lower dosage differed from the higher one in having a markedly lower incidence of side-effects. The results lead to the conclusion that a randomized double-blind phase-III clinical trial should be performed.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="f">Springer Online Journal Archives 1860-2002</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lemmel, E. M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Franke, M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gaus, W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hartl, P. W.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hofschneider, P. H.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Miehlke, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Machalke, K.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Obert, H. J.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">in</subfield><subfield code="t">Rheumatology international</subfield><subfield code="d">1981</subfield><subfield code="g">7(1987) vom: März, Seite 127-132</subfield><subfield code="w">(DE-627)NLEJ188987827</subfield><subfield code="w">(DE-600)1464208-6</subfield><subfield code="x">1437-160X</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:7</subfield><subfield code="g">year:1987</subfield><subfield code="g">month:03</subfield><subfield code="g">pages:127-132</subfield><subfield code="g">extent:6</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1007/BF00270465</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-SOJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">7</subfield><subfield code="j">1987</subfield><subfield code="c">3</subfield><subfield code="h">127-132</subfield><subfield code="g">6</subfield></datafield></record></collection>
|
| score |
7.3998156 |